HARMONY BIOSCIENCES

Lobbying for HARMONY BIOSCIENCES · pharmaceuticals

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 17, 2025

Expenses

$150,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Pennsylvania

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 9

HR 5547
Maintaining Investments in New Innovation Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 6094
Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act
HR 6664
Innovation in Pediatric Drugs Act of 2023
HR 7384
Creating Hope Reauthorization Act of 2024
HR 7383
RARE Act
HR 7024
Tax Relief for American Families and Workers Act of 2024
HR 3433
Give Kids a Chance Act of 2024
S 2897
Give Kids a Chance Act of 2023

Lobbying activity 1

Pharmacy

H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.